Dowpharma agrees Pfenex expression technology licence deal with Iomai
Dowpharma has set up a license agreement with private biopharmaceutical company Iomai Corporation in the US for its Pfenex expression technology, a Pseudomonas-based technology that accelerates speed to market for vaccines and biotherapeutics.
Dowpharma has set up a license agreement with private biopharmaceutical company Iomai Corporation in the US for its Pfenex expression technology, a Pseudomonas-based technology that accelerates speed to market for vaccines and biotherapeutics.
Under the agreement, Iomai will use the Pfenex expression technology for production of heat labile enterotoxin (LT), a key component of its transcutaneous immunisation platform technology for the delivery of vaccines to the skin.
Iomai will initially produce LT for use as a vaccine to treat enterotoxigenic Escherichia coli (ETEC) - the most common cause of acute diarrhoea among travellers to developing countries.
Stanley Erck, president and ceo at Iomai, said: 'We believe that Pfenex will enable us to increase the expression of our protein and deliver higher yields to support the advancement of our ETEC vaccine towards regulatory approval.'